Literature DB >> 18419434

Pneumococcal necrotizing pneumonia in Utah: does serotype matter?

Jeffrey M Bender1, Krow Ampofo, Kent Korgenski, Judy Daly, Andrew T Pavia, Edward O Mason, Carrie L Byington.   

Abstract

BACKGROUND: Streptococcus pneumoniae is the most common cause of bacterial pneumonia in children. Despite the use of the 7-valent pneumococcal conjugate vaccine, the incidence of pneumococcal necrotizing pneumonia (PNP) has been increasing. Our objectives were to describe temporal trends in PNP and to evaluate pneumococcal serotypes associated with PNP in Utah.
METHODS: We performed a retrospective review of all children <18 years of age who were cared for at a tertiary care children's hospital and who had blood, lung tissue, broncheoalveolar lavage, or pleural fluid cultures that grew S. pneumoniae, as well as radiographic evidence of pneumonia, from January 1997 through March 2006. All S. pneumoniae isolates were typed.
RESULTS: A total of 124 children with pneumococcal pneumonia were identified, and 33 (27%) of these children had radiographic evidence of PNP. During the period 1997-2000, 5 (13%) of 39 cases of culture-confirmed pneumococcal pneumonia were associated with PNP. In contrast, during the period 2001-2006, 28 (33%) of 85 pneumococcal pneumonia cases were complicated by PNP (odds ratio, 3.34; 95% confidence interval, 1.11-12.03). Non-7-valent pneumococcal conjugate vaccine serotypes comprised 49% of the isolates during 1997-2000 and 88% of isolates during 2001-2006 (odds ratio, 7.89; 95% confidence interval, 2.91-21.90). Pneumonia due to serotype 3 was most often associated with PNP. Eleven (79%) of 14 cases of serotype 3-associated pneumonia were associated with PNP. When compared with all other serotypes, serotype 3 was strongly associated with necrosis (odds ratio, 14.67; 95% confidence interval, 3.39-86.25).
CONCLUSIONS: PNP is a serious and increasingly common complication of S. pneumoniae pneumonia in Utah. Infection with serotype 3 is associated with an increased risk of developing PNP. The increase in the incidence of infection due to nonvaccine serotypes reported worldwide and the changing epidemiology of invasive pneumococcal disease should be considered when developing vaccine strategies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18419434      PMCID: PMC3673544          DOI: 10.1086/586747

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  31 in total

1.  Molecular typing of pneumococci causing parapneumonic empyema in Spanish children using multilocus sequence typing directly on pleural fluid samples.

Authors:  Ignacio Obando; Luis A Arroyo; David Sánchez-Tatay; David Moreno; William P Hausdorff; Angela B Brueggemann
Journal:  Pediatr Infect Dis J       Date:  2006-10       Impact factor: 2.129

2.  Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine.

Authors:  Marc Lipsitch; Keith O'Neill; Derrick Cordy; Boris Bugalter; Krzysztof Trzcinski; Claudette M Thompson; Richard Goldstein; Stephen Pelton; Heather Huot; Valerie Bouchet; Raymond Reid; Mathuram Santosham; Katherine L O'Brien
Journal:  J Infect Dis       Date:  2007-09-17       Impact factor: 5.226

3.  Radiographic, clinical, and prognostic features of complicated and uncomplicated community-acquired lobar pneumonia in children.

Authors:  Chao-Jen Lin; Po-Yen Chen; Fang-Liang Huang; Tain Lee; Ching-Shiang Chi; Ching-Yuang Lin
Journal:  J Microbiol Immunol Infect       Date:  2006-12       Impact factor: 4.399

4.  Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study.

Authors:  Cynthia G Whitney; Tamar Pilishvili; Monica M Farley; William Schaffner; Allen S Craig; Ruth Lynfield; Ann-Christine Nyquist; Kenneth A Gershman; Marietta Vazquez; Nancy M Bennett; Arthur Reingold; Ann Thomas; Mary P Glode; Elizabeth R Zell; James H Jorgensen; Bernard Beall; Anne Schuchat
Journal:  Lancet       Date:  2006-10-28       Impact factor: 79.321

5.  Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage.

Authors:  Rosalyn J Singleton; Thomas W Hennessy; Lisa R Bulkow; Laura L Hammitt; Tammy Zulz; Debby A Hurlburt; Jay C Butler; Karen Rudolph; Alan Parkinson
Journal:  JAMA       Date:  2007-04-25       Impact factor: 56.272

6.  National, state, and local area vaccination coverage among children aged 19-35 months--United States, 2006.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2007-08-31       Impact factor: 17.586

7.  Pneumococci responsible for invasive disease and discharging ears in children in Sydney, Australia.

Authors:  Michael Watson; Maggie Brett; Mitchell Brown; Marianne G Stewart; Shirley Warren
Journal:  J Med Microbiol       Date:  2007-06       Impact factor: 2.472

8.  Risk factors for pediatric invasive pneumococcal disease in the Intermountain West, 1996-2002.

Authors:  Maryam B Haddad; Christina A Porucznik; Kerry E Joyce; Anindya K De; Andrew T Pavia; Robert T Rolfs; Carrie L Byington
Journal:  Ann Epidemiol       Date:  2008-02       Impact factor: 3.797

9.  Impact of the pneumococcal conjugate vaccine on serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates in Dallas, TX, children from 1999 through 2005.

Authors:  Allison F Messina; Kathy Katz-Gaynor; Theresa Barton; Naveed Ahmad; Faryal Ghaffar; David Rasko; George H McCracken
Journal:  Pediatr Infect Dis J       Date:  2007-06       Impact factor: 2.129

10.  Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.

Authors:  Stephen I Pelton; Heather Huot; Jonathan A Finkelstein; C J Bishop; Katherine K Hsu; Joan Kellenberg; Susan S Huang; Richard Goldstein; William P Hanage
Journal:  Pediatr Infect Dis J       Date:  2007-06       Impact factor: 2.129

View more
  36 in total

1.  The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America.

Authors:  John S Bradley; Carrie L Byington; Samir S Shah; Brian Alverson; Edward R Carter; Christopher Harrison; Sheldon L Kaplan; Sharon E Mace; George H McCracken; Matthew R Moore; Shawn D St Peter; Jana A Stockwell; Jack T Swanson
Journal:  Clin Infect Dis       Date:  2011-08-31       Impact factor: 9.079

2.  Continued impact of pneumococcal conjugate vaccine on carriage in young children.

Authors:  Susan S Huang; Virginia L Hinrichsen; Abbie E Stevenson; Sheryl L Rifas-Shiman; Ken Kleinman; Stephen I Pelton; Marc Lipsitch; William P Hanage; Grace M Lee; Jonathan A Finkelstein
Journal:  Pediatrics       Date:  2009-07       Impact factor: 7.124

3.  Aggregation of Streptococcus pneumoniae by a pneumococcal capsular polysaccharide-specific human monoclonal IgM correlates with antibody efficacy in vivo.

Authors:  Kevin Fabrizio; Catherine Manix; Allan J Guimaraes; Joshua D Nosanchuk; Liise-Anne Pirofski
Journal:  Clin Vaccine Immunol       Date:  2010-03-03

4.  Necrotizing pneumonia in adults: multidisciplinary management.

Authors:  Marco Alifano; Christine Lorut; Aurelie Lefebvre; Lyna Khattar; Diane Damotte; Gerard Huchon; Jean-Francois Regnard; Antoine Rabbat
Journal:  Intensive Care Med       Date:  2011-08-05       Impact factor: 17.440

Review 5.  Antimicrobial resistance and virulence: a successful or deleterious association in the bacterial world?

Authors:  Alejandro Beceiro; María Tomás; Germán Bou
Journal:  Clin Microbiol Rev       Date:  2013-04       Impact factor: 26.132

6.  Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers.

Authors:  Susanna Esposito; Susan Tansey; Allison Thompson; Ahmad Razmpour; John Liang; Thomas R Jones; Giuseppe Ferrera; Alessandro Maida; Gianni Bona; Caterina Sabatini; Lorenza Pugni; Emilio A Emini; William C Gruber; Daniel A Scott; Nicola Principi
Journal:  Clin Vaccine Immunol       Date:  2010-04-28

7.  Are risk factors associated with invasive pneumococcal disease according to different serotypes?

Authors:  Pilar Ciruela; Núria Soldevila; Laura Selva; Sergi Hernández; Juan Jose Garcia-Garcia; Fernando Moraga; Mariona F de Sevilla; Gemma Codina; Ana Maria Planes; Cristina Esteva; Francis Coll; Neus Cardeñosa; Iolanda Jordan; Joan Batalla; Luis Salleras; Carmen Muñoz-Almagro; Angela Domínguez
Journal:  Hum Vaccin Immunother       Date:  2013-01-07       Impact factor: 3.452

8.  An unusual pneumococcal sequence type is the predominant cause of serotype 3 invasive disease in South Africa.

Authors:  Kedibone M Mothibeli; Mignon du Plessis; Anne von Gottberg; Linda de Gouveia; Peter Adrian; Shabir A Madhi; Keith P Klugman
Journal:  J Clin Microbiol       Date:  2009-11-04       Impact factor: 5.948

9.  Severe necrotizing pneumonia in children, Houston, Texas, USA.

Authors:  Anupama S Kalaskar; Gloria P Heresi; Audrey Wanger; James R Murphy; Susan H Wootton
Journal:  Emerg Infect Dis       Date:  2009-10       Impact factor: 6.883

10.  Streptococcus pneumoniae serotype 3 among Costa Rican children with otitis media: clinical, epidemiological characteristics and antimicrobial resistance patterns.

Authors:  Arturo Abdelnour; Carolina Soley; Silvia Guevara; Nurith Porat; Ron Dagan; Adriano Arguedas
Journal:  BMC Pediatr       Date:  2009-08-14       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.